Summit Therapeutics Inc


Market Cap$3.17B

Compare Summit Therapeutics

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Summit Therapeutics IncSummit Therapeutics Inc-5.30%-500%-0.9
marketMarket Avg53.21.27%29%-1.3
OtherOther Avg331.70.49%11%3.90.8

Target Price by Analysts

85.2% upsideSummit Therapeutics Target Price DetailsTarget Price

Current Fair Value

101.6% downside

Overvalued by 101.6% based on the discounted cash flow analysis.

Share Statistics

Market cap$3.17 Billion
Enterprise Value$3.06 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$-1.45
Outstanding Shares701,979,596
Avg 30 Day Volume2,066,323


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-5.3
Price to Sales-
Price to Book Ratio-
Enterprise Value to Revenue13900.79
Enterprise Value to EBIT-5.26
Enterprise Value to Net Income-6
Total Debt to Enterprise0.04
Debt to Equity0.9

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Summit Therapeutics Inc